The instructions for use (ifu) lists cardiovascular injury that may require intervention (including perforation or dissection of vessels, ventricle, myocardium or valvular structures, annular tear or rupture) as a potential risk associated with the overall tvr procedure.
Cardiac aneurysms have been reported as a rare complication following surgical or transcatheter valve replacement.
This type of defect in the cardiac tissues or aortic wall can result from trauma during percutaneous valve implantation or additional in-valve balloon dilation on a heavily calcified native valve.
Percutaneous/surgical intervention may be required.
In this case, there was no allegation or indication a device malfunction contributed to this adverse event.
The exact cause of the aneurysm post procedure is unknown, however many be due to patient/procedural factors.
The ifu and training manuals have been reviewed and no inadequacies have been identified with regards to warnings, contraindications, and the directions/conditions for the successful use of the device.
Complaint histories for all reported events are reviewed against trending control limits on a monthly basis, and any excursions above the control limits are assessed and documented as part of this monthly review.
No corrective or preventative actions are required.
|
As reported, approximately 3 days post transcatheter pulmonic valve replacement (tpvr) with a 23mm sapien 3 valve, an aneurysm was observed, and a covered stent was implanted to repair the pulmonary artery aneurysm.
Next, a 2nd valve was placed within the covered stent.
The patient is stable post procedure.
|